Save
TREATMENT OF RECURRENT AND METASTATIC DISEASE
ESGO eAcademy, Ate van der Zee, 202749
CASE PRESENTATION 2 :SERTOLI LEYDIG CELL TUMOR
ESGO eAcademy, Cristiana Sessa, 202754
CASE PRESENTATION 2 :SERTOLI LEYDIG CELL TUMOR
ESGO eAcademy, Dominik Schneider, 202753
CASE PRESENTATION 1 :STAGE I GRADE 3 IMMATURE TERATOMA
ESGO eAcademy, Philippe Morice, 202752
CASE PRESENTATION 1 :STAGE I GRADE 3 IMMATURE TERATOMA
ESGO eAcademy, Gabriele Calaminus, 202751
DIAGNOSIS, STAGING AND PREOPERATIVE WORKUP
ESGO eAcademy, Maaike Oonk, 202747
Practical experiences from CTCA at Southeastern RegionalMedical Center, Georgia USA
ESGO eAcademy, Mansoor Raza Mirza, 202740
Pathological aspects of uterine carcinocarcoma
ESGO eAcademy, Mojgan Devouassoux, 202903
Practical experiences from Klinik für Gynäkologie, Die Charité – Universitätsmedizin Berlin, Germany
ESGO eAcademy, Jacek Grabowski, 202739
ROBOTIC EXPERT VIDEO
ESGO eAcademy, Rainer Kimmig, 261658
CONCLUSION
ESGO eAcademy, Andreas Du Bois, 202736
Q&A and Discussion
ESGO eAcademy, Session Speakers, 203120
SELECTING PATIENTS FOR PARP INHIBITION
ESGO eAcademy, Mansoor Mirza, 202735
RELAPSED OVARIAN CANCER: WHAT DOES MAINTENANCE THERAPY OFFER?
ESGO eAcademy, Nicoletta Colombo, 202733
Welcome and introduction
ESGO eAcademy, Christian Marth, 202732
QUESTIONS REMAINED TO BE ANSWERED
ESGO eAcademy, David Cibula, 202728
CIRCULATING TUMOR CELLS: CHALLENGES & PERSPECTIVES IN GYNAECOLOGICAL CANCERS
ESGO eAcademy, Catherine Alix-Panabieres, 202731
SLN IMPLEMENTATION INTO MANAGEMENT ALGORITHMS
ESGO eAcademy, Nadeem Abu Rustum, 202727
DETECTION OF METHYLATED DNA IN VARIOUS BODY FLUIDS AND THEIR USE AS DIAGNOSTIC, PROGNOSTIC AND PREDICTIVE TOOLS IN GYNAECOLOGICAL CANCERS
ESGO eAcademy, Heidi Fiegl, 202730
DEVELOPMENTS IN DETECTION TECHNIQUES
ESGO eAcademy, Eric Leblanc, 202726
WHOLE-GENOME SEQUENCING OF CELL-FREE DNA IN GYNAECOLOGICAL CANCERS
ESGO eAcademy, Adriaan Vanderstichele, 202729
Ultrasound Characteristics Of Endometrial Cancer As Defined By The International Endometrial Tumor Analysis (IETA) Consensus Nomenclature- A Prospective Multicenter Study
ESGO eAcademy, Daniela Fischerova, 202910
LION – LYMPHADENECTOMY IN OVARIAN NEOPLASMS. A PROSPECTIVE RANDOMIZED AGO STUDY GROUP LED GYNECOLOGIC CANCER INTERGROUP TRIAL.
ESGO eAcademy, Domenica Lorusso, 202722
UTERINE CORPUS
ESGO eAcademy, Sigurd Lax, 202725
WHAT MODIFIES THE OUTCOME OF RECURRENT GRANULOSA CELL TUMORS OF THE OVARY?
ESGO eAcademy, Isabel Carriles, 202721
OVARY AND FALLOPIAN TUBE
ESGO eAcademy, Matias-Guiu Guia, 202724
PRE-SURGICAL METFORMIN IN UTERINE MALIGNANCY-RESULTS OF THE PREMIUM RANDOMISED CONTROLLED TRIAL
ESGO eAcademy, Sarah Kitson, 202719
CERVIX, VULVA, VAGINA
ESGO eAcademy, Glenn McCluggage, 202723
Development And Pre-Testing Of The Eortc Quality Of Life Questionnaire For Vulva Cancer Patients – The Significance Of Patient Involvement
ESGO eAcademy, Pernille Jensen, 202909
Closing and remarks
ESGO eAcademy, Andreas Du Bois, 202716
Being Practical Case 3
ESGO eAcademy, Christian Marth, 202715
Being Practical Case 2
ESGO eAcademy, Nicoletta Colombo, 202714
Being Practical Case 1
ESGO eAcademy, Isabelle Ray-Coquard, 202713
SETTING THE SCENE: QUALITY OF LIFE IN OVARIAN CANCER, IS IT A KEY FACTOR FOR OUR DECISION MAKING?
ESGO eAcademy, Felix Hilpert, 202712
Introduction
ESGO eAcademy, Andreas Du Bois, 202711
Prognostic Factors For Local Recurrence Of Squamous Cell Carcinoma Of The Vulva: A Systematic Review
ESGO eAcademy, Nienke Te Grootenhuis, 202908
The New Normal; Sexual Function after Ovarian Cancer for Survivors and Partners Compared to Normdata
ESGO eAcademy, Maria Caroline Vos, 202907
HOW LONG SHOULD HORMONAL TREATMENT BE CONTINUED BEFORE DECIDING FOR HYSTERECTOMY IN THE FERTILITY SPARING MANAGEMENT OF ENDOMETRIAL CANCER?
ESGO eAcademy, Nicoletta Colombo, 202704
VULVA CANCER
ESGO eAcademy, Ate van der Zee, 202709
The Role Of The Peritoneal Cancer Index In Surgery For Advanced Ovarian Cancer
ESGO eAcademy, Mikkel Rosendahl, 202906
FERTILITY SPARING MANAGEMENT IN CERVICAL CANCERS BETWEEN 2 AND 4 CM: RADICAL TRACHELECTOMY BY LAPAROTOMY OR NEO-ADJUVANT CHEMOTHERAPY?
ESGO eAcademy, Ignace Vergote, 202703
OVARIAN CANCER
ESGO eAcademy, Christoph Grimm, 202708
The Peritoneal Cancer Index(PCI): Selted Regions - And Not The Total PCI - Are Predictive Of Survival In Advanced Ovarian Cancer
ESGO eAcademy, Mikkel Rosendahl, 202905
CAN WE SAFELY USE OVARIAN HYPERSTIMULATION IN INFERTILE PATIENTS AFTER FSS FOR EPITHELIAL TUMORS?
ESGO eAcademy, Dominik Denschlag, 202702
CERVICAL CANCER
ESGO eAcademy, Daniela Fischerova, 202707
FERTILITY SPARING MANAGEMENT IN HIGH RISK EPITHELIAL OVARIAN CANCER
ESGO eAcademy, Enrica Bentivegna, 202701
Imaging in the diagnosis and management of endometrial cancer
ESGO eAcademy, Ingfrid Haldorsen, 202706
CHANGES IN NEOANGIOGENETIC PROFILE OF PAIRED PRIMARY AND RECURRENT HIGH-GRADE SEROUS OVARIAN CANCER (HGOSC): A STUDY OF THE “OCTIPS” CONSORTIUM.
ESGO eAcademy, Ilary Ruscito, 202699
CISPLATIN CHEMO-RADIATION VERSUS RADIATION IN FIGO STAGE IIIB SQUAMOUS CELL CARCINOMA OF THE UTERINE CERVIX (CRACX TRIAL: NCT00193791)
ESGO eAcademy, Umesh Mahantshetty, 202698
AGO-OVAR 12: A RANDOMIZED PLACEBO-CONTROLLED GCIG/ENGOT-INTERGROUP PHASE III TRIAL WITH CHEMOTHERAPY +/- NINTEDANIB FOR ADVANCED OVARIAN CANCER: OVERALL SURVIVAL RESULTS
ESGO eAcademy, Isabelle Ray-Coquard, 202697
EMBRACE THE MOLECULAR CLASSIFICATION OF ENDOMETRIAL CANCER
ESGO eAcademy, Tjalling Bosse, 202696
Randomized Controlled Phase III Study To Evaluate Secondary Cytoreductive Surgery In Platinum-Sensitive Recurrent Ovarian Cancer - AGO Desktop III/ENGOT Ov20
ESGO eAcademy, Jalid Sehouli, 202904
Medical treatment of uterine carcinosarcoma
ESGO eAcademy, Isabelle Ray-Coquard, 190586
Surgical treatment of serous endometrial cancer
ESGO eAcademy, Frederic Guyon, 190585
Long- term therapy with gonadoliberin analogues in patient with ovarian cancer.
ESGO eAcademy, Session Speakers, 191006
High grade serous ovarian cancer stage IV, multiple relapses
ESGO eAcademy, Session Speakers, 191003
Ovarian Cancer in Pregnancy
ESGO eAcademy, Session Speakers, 190595
Surgical treatment of low grade serous ovarian cancer
ESGO eAcademy, Jalid Sehouli, 180471
Medical Tumor Therapy for Germ Cell Tumors of Adults
ESGO eAcademy, Michael Seckl, 180466
Systemic treatment for low grade serous carcinoma
ESGO eAcademy, Michael Seckl, 180469
Surgical treatment for malignant germ cell tumor.
ESGO eAcademy, Pauline Wimberger, 180467
Pathologic aspects of Germ Cell Tumors
ESGO eAcademy, Doris Mayr, 180468
Pathologic aspects of Low Grade Serous Ovarian Cancer
ESGO eAcademy, Doris Mayr, 180470
Look into the future: Medical treatment of ovarian cancer in 2026
ESGO eAcademy, Ignace Vergote, 173572
Immunotherapy in gynecological malignancies
ESGO eAcademy, An Coosemans, 173570
Why do studies of targeted treatment fail?
ESGO eAcademy, Jonathan Ledermann, 173568
Targeting PARP: Mechanisms of action, available evidence, selection of patients, management of toxicities
ESGO eAcademy, Jonathan Ledermann, 173567
Targeting tyrosine kinases
ESGO eAcademy, Jonathan Ledermann, 173566
Molecular pathways in cervical cancer
ESGO eAcademy, Heidi Lyng, 173565
Molecular pathways in endometrial cancer
ESGO eAcademy, Henrica Maria Johanna Werner, 173564
Molecular pathways of low-grade ovarian cancer
ESGO eAcademy, Kristina Lindemann, 173563
Molecular pathways of high grade ovarian cancer
ESGO eAcademy, Adriaan Vanderstichele, 173562
Surgical aspects of uterine carcinosarcoma (~ serous)
ESGO eAcademy, Frederic Amant, 173558
Ultrasound guided procedures
ESGO eAcademy, Michal Zikan, 173920
Ovarian cancer staging
ESGO eAcademy, Daniela Fischerova, 173919
Endometrial cancer diagnosis and staging
ESGO eAcademy, Elisabeth Epstein, 173918
Cervical cancer staging
ESGO eAcademy, Antonia Testa, 173917
Abdominal scan
ESGO eAcademy, Daniela Fischerova, 173916
Pelvic imaging
ESGO eAcademy, Daniela Fischerova, 173915
Introduction
ESGO eAcademy, David Cibula, 173914
Uterine carcinosarcoma: radiotherapy
ESGO eAcademy, Carien Creutzberg, 173556
Serous endometrial cancer: radiotherapy
ESGO eAcademy, Carien Creutzberg, 173557
Serous endometrial cancer: current management and targeted therapies
ESGO eAcademy, Annamaria Ferrero, 173555
PMMR in endometrial cancer - Part one - Compartmental lymphatic network of uterine corpus and its drainage
ESGO eAcademy, Rainer Kimmig, 166631
PMMR in endometrial cancer - Part two - Surgical technique
ESGO eAcademy, Rainer Kimmig, 166632
Adjuvant Treatment and Place of Radiation Therapy in Vulvar Cancer
ESGO eAcademy, Carien Creutzberg, 150846
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
ESGO eAcademy, Mansoor Raza Mirza, 154789
New ESGO Guidelines of Management of Vulvar Cancer
ESGO eAcademy, Ate van der Zee, 150845
How to Stage Locally Advanced Cervical Cancer (Radiological and Surgical) before Chemoradiation Therapy
ESGO eAcademy, Sebastien Gouy, 150844
Management of the Clear Cell Ovarian Carcinoma
ESGO eAcademy, Keiichi Fujiwara, 150843
Phase 2: What Information Can We Derive? Rational, Design and Objectives
ESGO eAcademy, Jonathan Ledermann, 150268
Surrogate Endpoints
ESGO eAcademy, Paolo Bruzzi, 150266
Phase 1/1B: What Information Can We Derive? Rational, Design and Objectives
ESGO eAcademy, Cristiana Sessa, 150267
Statistical Plans, Interim Analysis and Subgroup Analysis
ESGO eAcademy, Paolo Bruzzi, 150265
Vulvar Cancer: What Do We Know? What Don't We Know? What Should Be Investigated?
ESGO eAcademy, Fabio Landoni, 150264
Endometrial Cancer: What Do We Know? What Don't We Know ? What Should Be Investigated?
ESGO eAcademy, Eric Pujade-Lauraine, 150263
Uterine Sarcoma: What Do We Know? What Don't We Know? What Should Be Investigated?
ESGO eAcademy, Andres Poveda, 150262
Cervical Cancer: What Do We Know? What Don't We Know? What Should Be Investigated?
ESGO eAcademy, Christian Marth, 150261
Welcome & Introduction
ESGO eAcademy, Nicoletta Colombo, 150269
New Classification of Uterine Sarcoma
ESGO eAcademy, Sabrina Croce, 147380

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings